Allogene Therapeutics
ALLO | NASDAQ
$0.81
-$0.03 (-3.42%)
At close: Nov 16, 2026, 4:00 PM ET
$0.81
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-3.42%
(1D)No price chart data available for 1D timeframe.
Rating
52.5
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #221/1021 (Top 22%)
Key Statistics
Market Data
Market Cap $279.6M
1D Range
0.77 0.85
52W Range
0.77 3.06
Valuation (TTM)
PE -1.29
PB 0.71
EV/EBITDA -0.32
Valuation (NTM)
Forward PE N/A
Forward PEG 0.04
Price Target $6.43
Cash Flow
FCF Yield -38.9%
SBC Adj. FCF Yield -51.7%
SBC Impact -33.0%
Margins
Gross Margin 100.0%
Operating Margin -4099.3%
FCF Margin -2345.0%
Growth (CAGR)
Revenue 3Y | 5Y 237.2% |
-34.5%
Dil EPS 3Y | 5Y 44.0% |
28.9%
FCF 3Y | 5Y 33.7% |
15.3%
Returns
ROA -34.1%
ROE -49.8%
ROIC -40.2%
Financial Health
Net Cash
$224.92M
Current Ratio 7.79
Interest Coverage -142.48
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of...
Sector Healthcare
Industry Biotechnology
Employees 151
IPO Date Oct 11, 2018
Website www.allogene.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
9
Consensus
Buy
Price Target
$6.43
Upside
+693.83%
Buy (6)
Hold (3)
Sell (0)
Add to Watchlist
Select watchlists to add or remove ALLO